A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

Phase 1 Completed 35 enrolled Lux Biosciences, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.

Timeline

Start: 2009-02
Primary completion: 2009-03
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Voclosporin	Other / unclassified	0.02 %	—
Subject	Voclosporin	Other / unclassified	0.2 %	—

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

Summary

Timeline

Drugs

Indications